INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 453m ago
HOUSE PTR52m ago
SEC 13F52m ago
ROBINHOOD CHAIN52m ago
SEC FORM 4/Open-market purchaseVerified data

Khan Bilal Arshad bought SGP

Director · SpyGlass Pharma, Inc. · Common Stock

Side
BUY
Value
$320K
Shares
20.0K
Price
$16
Executed
Feb 9, 2026
Disclosed
Feb 11, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Feb 9 executedFeb 11, 2026 disclosed

SGP · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
47/ 100 · ELEVATED
Methodology →
  • Transaction type+20 / 20

    Open-market purchase

  • Relative size+19 / 25

    $320K reported value · 367.0% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · SGP

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    50
    KA
    Khan Bilal ArshadDirector
    SGPSpyGlass Pharma, Inc.
    Open-market purchase
    		BUY$1.84M
    115.0K sh
    		Feb 9, 2026Feb 11, 2026
    traded Feb 9, 2026
    		+2dSEC FORM 4

    Evidence

    9
    KY
    Kahook Malik Y.Director, See remarks
    SGPSpyGlass Pharma, Inc.
    Grant or award
    		A—
    105.0K sh
    		Feb 5, 2026Feb 9, 2026
    traded Feb 5, 2026
    		+4dSEC FORM 4

    Evidence

    9
    MH
    Mooney Patrick H.Director, Chief Executive Officer
    SGPSpyGlass Pharma, Inc.
    Grant or award
    		A—
    300.0K sh
    		Feb 5, 2026Feb 9, 2026
    traded Feb 5, 2026
    		+4dSEC FORM 4

    Evidence

    9
    PP
    Pujara Chetan PratapChief R&D Officer
    SGPSpyGlass Pharma, Inc.
    Grant or award
    		A—
    105.0K sh
    		Feb 5, 2026Feb 9, 2026
    traded Feb 5, 2026
    		+4dSEC FORM 4

    Evidence

    9
    DR
    Dennewill James Robert Jr.Chief Operating Officer
    SGPSpyGlass Pharma, Inc.
    Grant or award
    		A—
    105.0K sh
    		Feb 5, 2026Feb 9, 2026
    traded Feb 5, 2026
    		+4dSEC FORM 4

    Evidence

    9
    SZ
    Scheiner ZacharyDirector
    SGPSpyGlass Pharma, Inc.
    Grant or award
    		A—
    27.4K sh
    		Feb 5, 2026Feb 9, 2026
    traded Feb 5, 2026
    		+4dSEC FORM 4

    Evidence

    9
    KA
    Khan Bilal ArshadDirector
    SGPSpyGlass Pharma, Inc.
    Grant or award
    		A—
    13.7K sh
    		Feb 5, 2026Feb 9, 2026
    traded Feb 5, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002108044-26-000006
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Feb 9, 2026
    Published
    Feb 11, 2026
    Ingested by INSIDER
    Nov 5, 04:17 UTC
    Last re-read
    Nov 5, 04:17 UTC

    Extracted facts

    Filer
    Khan Bilal Arshad
    Role
    Director
    Transaction
    Open-market purchaseAs filed: “P”
    Asset
    SpyGlass Pharma, Inc.
    Ticker
    SGP
    Shares
    20.0K
    Price per share
    $16
    Value
    $320,000
    Execution date (reported)
    Feb 9, 2026
    Owned after transaction
    25.4K shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 20.0K
    • Price: $16

    = $320,000

    What this establishes

    Khan Bilal Arshad filed this Form 4 reporting a open-market purchase of SGP on Feb 9, 2026. It became public on Feb 11, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Khan Bilal Arshadcik:0002108044
    Issuer
    SpyGlass Pharma, Inc.cik:0001778922

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.